ClinicalTrials.gg
CompletedNCT04024956SHIELDSUpdated Jul 3, 2023

Safety and Performance of a Synthetic Tissue Sealant in Reducing Fluid Leakage in Hepatobiliary and Pancreatic Surgery

An interventional study of Sealing Device in Pancreatectomy and Hepatic Resection, sponsored by Polyganics BV. Completed at 2 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-03.

Sponsored by Polyganics BV · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Polyganics BV (Groningen, The Netherlands), in close collaboration with University Hospital-Eppendorf (UKE) Hamburg, has developed the Sealing Device for use in hepato-pancreato-bilary (HPB) surgery to reduce leakage of fluids from the site of surgery into the abdominal cavity and as an adjunctive hemostatic device to control minimal to moderate bleeding at the surgical site. The Sealing Device has been challenged in pre-clinical testing (laboratory and in-vivo work), but has not been evaluated for safety and performance in humans.

This investigation will be conducted to clinically assess the safety and performance of Sealing Device as a means to reduce bile and pancreatic juice leakage in hepato-pancreato-bilary (HPB) surgery. Secondarily, the control of minimal to moderate bleeding will be assessed. To achieve adequate representation of the primary objective, the study will contain two separate surgical patient groups: Liver and Pancreas.

The primary objective of the study is to demonstrate safety and performance in reducing intra- and post-operative leakage (bile and pancreatic juices) by using the Sealing Device in patients undergoing elective hepatic resection or distal pancreatectomy.

The study will be conducted as an open-label, single-arm, multicenter study with a 16 months follow up. Up to 80 patients (40 liver and 40 pancreas patients) will be enrolled at up to 7 sites in Europe.

02

Conditions studied

  • Pancreatectomy
  • Hepatic Resection

Keywords

  • Hepatic resection
  • Distal pancreatectomy
  • Sealant
03

In context

Lead sponsor

Polyganics BV is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Preoperative inclusion criteria:

Subjects will be eligible according the following criteria:

  1. Subjects who are able to provide a written prior to participating in the clinical investigation.
  2. Subjects who are ≥ 18 years old.
  3. Subjects who are able to comply with the follow-up or other requirements.
  4. Subjects who are planned for an elective hepatic resection or distal pancreatectomy.

During the surgery, the patients also need to comply with the intraoperative criteria.

Intraoperative inclusion criteria:

Subjects will be eligible according the following criteria:

  1. Patch is applied manually (during open procedure, conversion procedure, or laparoscopic assisted procedure).

Exclusion criteria

Exclusion Criteria:

Preoperative exclusion criteria

Subjects who meet any of the following criteria will be excluded from participation:

  1. Female subjects who are pregnant and/or breastfeeding.
  2. Subjects with a known allergy to any of the components of the Sealing Device (Polyurethane (SDPU), 8-ArmPEG40k-SC (SDA), Disodium Hydrogen Phosphate (Na2HPO4) (BS) and DC-Green #6 (SDD)).
  3. Subject with bleeding disorders requiring anti-coagulation medication (except acetylsalicylic acid).
  4. Subjects who receive double-coagulation.
  5. Subjects who receive peritoneal dialysis.
  6. Subjects who previously required liver transplantation.
  7. Subjects with a presence of systemic infection.
  8. Subject who previously participated in this study, or in any drug- or device study within 30 days of screening.
  9. Subjects undergoing a procedure requiring an anastomosis (e.g. Klatskin tumours or Whipple).

Intraoperative exclusion criteria:

Subjects who meet any of the following criteria will be excluded from participation:

  1. Subjects with multivisceral resections, except resection of spleen.
  2. Not able to apply the patch(es) according to the Instructions For Use.
  3. Total surgery requiring > 3 HPB Sealing Devices of 10 x 5 cm (which equals a resection surface of more than 88cm2).

    Additional for liver group:

  4. Subjects with a Grade 3 or 4 of bleeding after primary closure after liver transection (Lewis 2016).
  5. Subjects with liver cirrhosis Grade C on the Child-Turcotte-Pugh score.

    Additional for pancreas group:

  6. Subjects with a margin of \< 1 cm between the defect and the portal vein.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Sealing Device

    Sealing Device applied in hepatic resection or distal pancreatectomy

    Device: Sealing Device

Interventions

  • DeviceSealing Device

    The Sealing Device is indicated for use in hepato-pancreato-biliary (HPB) surgery to reduce leakage of fluids from the site of surgery into the abdominal cavity and as an adjunctive hemostatic device to control minimal to moderate bleeding at the surgical site.

06

What researchers measure

Primary outcomes

  1. Bile leakage

    Incidence of post-operative bile leakage (International Study Group of Liver Surgery Bile leakage Grading Scale); categories in order of ascending severity: biochemical leak, Grade B or Grade C

    Time frame: 30 days

  2. Pancreatic leakage

    Incidence of post-operative pancreatic juice leakage (International Study Group of Pancreas Surgery Grading Scale); categories in order of ascending severity: biochemical leak, Grade B or Grade C

    Time frame: 30 days

Secondary outcomes

  1. Bleeding

    Intra-operative control bleeding

    Time frame: Day 1

  2. Leak-associated comorbidities

    Incidence of leak-associated comorbidities

    Time frame: 16 months

  3. re-intervention

    Incidence of re-intervention

    Time frame: 16 months

  4. Ease of Use

    Ease of Use of the device as measured by questionnaire

    Time frame: Day 1

  5. Post-operative bile leakage

    Incidence of post-operative bile leakage (liver only)

    Time frame: 90 and 180 days

  6. Post-hepatectomy haemorrhage (PHH)

    Incidence of post-operative bleeding (liver only)

    Time frame: 30 days

  7. Post-operative pancreatic juice leakage

    Incidence of post-operative pancreatic juice leakage (pancreas only)

    Time frame: 90 and 180 days

  8. Post-pancreatectomy haemorrhage (PPH)

    Incidence of post-operative bleeding (pancreas only)

    Time frame: 30 days

  9. (Serious) Adverse Device Effects

    Incidence of (Serious) Adverse Device Effects

    Time frame: 16 months

  10. Incidence of transfusion

    Incidence of transfusion

    Time frame: 16 months

  11. Length of hospital stay

    Length of hospital stay

    Time frame: 30 days

07

Study locations

2 sites
  • Universitats Klinikum Hamburg-Eppendorf
    Hamburg, Germany
  • University Hospital Oldenburg
    Oldenburg, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Nov 2021, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2019
First posted
Jul 18, 2019
StartActual
Aug 25, 2020
Primary completionActual
Nov 19, 2021
CompletionActual
May 26, 2023
Last update
Jul 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04024956
Lead sponsor
Polyganics BV
Collaborators
Genae
Responsible party
Sponsor
First posted
Jul 18, 2019
Start date
Aug 25, 2020
Primary completion
Nov 19, 2021
Completion
May 26, 2023
Last update
Jul 3, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion